Back to Basics Review:Respirology in Under Two Hours
Nha Voduc MD FRCPCOriginal Presentation by Jen Block MD FRCPC
April 8, 2011
The Plan...
• Pulmonary Function Testing
• Asthma
• COPD
• Sleep Apnea
• Pleural Effusion
• Lung Cancer
Spirometry: Measurement of Airflow
1. Take as deep a breath as possible2. Blast out the air into spirometer3. Continue exhaling for several more seconds
UpToDate
RVTLC
Flow Volume Loop
Interpretation
• Upper Airway Abnormalities
• Obstructive Lung Disease
• Restrictive Lung Disease
Upper Airway Abnormalities
• Variable extrathoracic obstruction impairs inspiratory flow more than expiratory flow -- negative pressure during inspiratory “sucks in” (narrows) airway
• Variable intrathoracic obstruction impairs expiratory flow more than inspiratory flow -- positive intrathoracic pressure compresses in airway
ERJ 2005; 26: 948-968
Obstructive Lung Disease
• FEV1/FVC is <70%and
• FEV1 < 80%(or < 2 standard deviations)
• “scooped out”
• lung volumes may show Hyperinflation or “gas trapping”(increased residual volume)
ERJ 2005; 26: 948-968
Restrictive Lung Disease
• TLC < 80% (or < 2 standard deviations)
• normal FEV1/FVC ratio
• Neuromuscular, Chest wall,
Interstitial Lung disease
ERJ 2005; 26: 948-968
Asthma
• Pathophysiology
• Diagnosis
• Chronic Management
• Acute Management
Asthma: Definition
• paroxysmal or persistent symptoms (dyspnea, chest tightness, wheeze, cough)
• variable airflow limitation and airway hyper-responsiveness
• due to inflammation
Comprehensive Asthma Management
• Suspect asthma and confirm diagnosis
• Education
• Assess severity
• Avoid / control triggers and environmental modification
• Medications for chronic disease
• Assess control
• Management plan for exacerbation
• Regular follow-up
• If FEV1 is low, try to increase it using a short-acting bronchodilator
(reversibility)
• ≥12% and ≥180 ml improvement in FEV1 from baseline 15 minutes after the
use of an inhaled short-acting bronchodilator
Asthma Diagnosis: Requirements PFTs
• If FEV1 is normal, try to see if airways are hyperresponsive by giving an
irritant (methacholine challenge)
Asthma Diagnosis
Comprehensive Asthma Management
• Suspect asthma and confirm diagnosis
• Education
• Assess severity
• Avoid / control triggers and environmental modification
• Medications for chronic disease
• Assess control
• Management plan for exacerbation
• Regular follow-up
Asthma Management
Relievers – Short Acting Beta-Agonists
• SABAs for acute relief• ‘rescue’ medication used as needed• MDI salbutamol (Ventolin) • dry powder terbutaline (Bricanyl)
• Frequent use of SABA indicates poor control• Regular use associated with tachyphylaxis
Asthma Management
Inhaled Corticosteroids (ICS)
• Anti-inflammatory ICS mainstay of therapy
– Prevent symptoms, improve PFTs, decrease hyper-responsiveness, reduce morbidity
Inhaled Corticosteroids – How do they work?
• Like steroids produced endogenously by adrenal cortex
• Anti-inflammatory – inhibit production of cytokines, which:
– reduces eosinophil infiltration– inhibits macrophage function– reduces production of leukotrienes
Dosing Guide
Drug Low Daily Dose (μg) Medium Dose (μg) High Daily Dose (μg)
Fluticasone(Flovent)
≤250 251-500 >500
Budesonide(Pulmicort)
≤400 401-800 >800
Beclomethasone(Qvar)
≤250 251-500 >500
Ciclesonide(Alvesco)
≤200 201-400 >400
ICS Adverse Effects
• thrush• dysphonia
• osteoporosis• decreasedgrowth velocity (?)• glaucoma • cataracts• adrenal insufficiency
Asthma Management
Long Acting β2-Agonists (LABAs)
• add if not controlled by moderate dose ICS
• better than doubling ICS
• “not recommended as maintenance monotherapy”
– Increased mortality!
• doesn’t replace SABAs
• salmeterol (Serevent), formoterol (Oxeze)
Combination LABA / ICS Products
– Salmeterol/fluticasone (Advair) MDI and diskus
– Budesonide/formoterol (Symbicort) turbuhaler
Leukotriene Receptor Antagonists (LTRAs)
• Second or third choice medication or in patients who can’t take ICS
• Montelukast (Singulair)
• Oral medication
• Use in patients with:
– symptoms despite LABA/ICS
– ASA sensitivity, nasal polyps
– exercise-induced asthma
IgE Antagonists: Omalizumab (Xolair)
• Monoclonal antibodies block action of IgE on mast cell
• Effective if IgE levels are only slightly elevated (500-1200)
• Monthly injection
• Extremely expensive
• Use if frequent need for oral steroids despite optimum conventional Rx and patient has drug plan or $$$
Comprehensive Asthma Management
• Suspect asthma and confirm diagnosis
• Education
• Assess severity
• Avoid / control triggers and environmental modification
• Medications for chronic disease
• Assess control
• Management plan for exacerbation
• Regular follow-up
Assess Control
• Both physicians and patients over-estimate their degree of control (many patients are much worse than they think they are)
Comprehensive Asthma Management
• Suspect asthma and confirm diagnosis
• Education
• Assess severity
• Avoid / control triggers and environmental modification
• Medications for chronic disease
• Assess control
• Management plan for exacerbation
• Regular follow-up
Asthma Exacerbation
• ABC’s– include RR, O2 sats, assess work of breathing, wheezing
• history: – Diagnosis– Environmental triggers– Previous exacerbations/admissions/intubations– Treatment history
• Compliance• Inhaler technique
– Other medical illnesses or medications
• short-acting beta-agonists ie. salbutamol (Ventolin)
• short-acting anti-cholinergics ie. ipratropium (Atrovent)
• systemic anti-inflammatory therapy– oral = prednisone– intravenous = solumedrol
• very severe: MgSO4, intubation, anesthetic
Asthma Exacerbation
COPD
• Definition
• Constrast from asthma
• Pathophysiology
• Diagnosis
• Chronic Management
• Acute Management
COPD Definition
• respiratory disorder largely caused by smoking characterized by:
- progressive, partially reversible airway obstruction
- hyperinflation
- systemic manifestations
- increasing frequency and severity of exacerbations
COPD Risk Factors
• Host Factors:
- genetics (alpha-1-antitrypsin deficiency)
- bronchial hyper-responsiveness
• Environmental Factors:
- smoking
- childhood viral infections
- occupational & environmental exposures
Pathophysiology - Airflow Obstruction
• alveoli and support structures are destroyed– decreased elastic recoil– lack of tethering gives airway collapse
• airway compression by adjacent overdistended lung units
• mucosal inflammation and secretions
Pathophysiology - Hyperinflation
• expiratory flow limitation in COPD results in air trapping
• end-expiratory lung volumes are increased
• further hyperinflation with exercise (increased respiratory rate results in decreased expiratory time)
• decreased inspiratory capacity a major cause of dyspnea– Increased load on inspiratory
muscles
COPD Diagnosis
• do not screen asymptomatic individuals
• assess symptomatic patients with spirometry
• post-bronchodilator FEV1/FVC ratio less than 0.7
COPD Stage Post-bronchodilator FEV1
(% predicted)
mild ≥ 80
moderate 50 - 79
severe 30 - 49
very severe < 30
COPD Management
BMJ 2008; 336: 598-600.
Education - Effects of Smoking on FEV1
Mortality Benefit
Education
“Tobacco is the only legal consumer product that kills
one third to one half of those who use it as intended
by its manufacturers, with its victims dying on
average 15 years prematurely”
- World Health Organization
What Can You Do?
• 2007: 19% of adult Canadians are active smokers
• smoking cessation advice– even brief advice increases chances of patients quitting
• Personalized, direct but non-judgmental message
– www.gosmokefree.ca– www.smokershelpline.ca
• nicotine replacement therapy– many different types– any form of NRT increases chances of quitting vs. control
• buproprion, varenicline
Other Prevention
• vaccination:– flu vaccine yearly– pneumococcal vaccine q5years
COPD Management
Short-Acting Bronchodilators
• Even patients with “fixed” airflow obstruction can have good clinical response to bronchodilators even if FEV1 changes very little
• Reduces hyperinflation, reduces dyspnea and increases exercise capacity
Short-Acting Bronchodilators
• anti-cholingergics: ipatropium (Atrovent)– dry mouth– glaucoma if sprayed into eye– urinary retention
• β2-agonists: salbutamol (Ventolin)– tachycardia, palpitations– sleeplessness, tremor
• improves PFTS, dyspnea and exercise performance
COPD Management
Long-acting anti-cholinergic
• tiotropium (Spiriva)
• once a day
• blocks M3 muscarinic receptors in bronchial
smooth muscle
• improves:– PFTs, dyspnea, exercise capacity, quality of life– decreases exacerbations– maybe more improvement than LABA
Long-acting β2-agonist (LABA)
• salmeterol (Serevent) and formoterol (Oxeze)
• twice daily
• more sustained improvement in PFTs, dyspnea and QOL than short-
acting bronchodilators
COPD Management
Dyspnea – Downward Spiral of Deconditioning
Respiratoryimpairment
Dyspnea during moderate exertion
Abstentionfrom exercise
Physical deconditioning
Dyspnea during mild exertion
Furtherabstention
Furtherdeconditioning
Dyspneaduring ADL
*
* = stay at home. Depression, oxygen
therapy etc.
Pulmonary Rehabilitation
– Exercise + psychosocial support
– Aerobic exercise + strength training
– improves dyspnea, endurance, QOL
– trend to decreasing mortality
– need a maintenance program
www.lungchicago.org www.altru.org
COPD Management
Combination LABA / ICS Products
– Salmeterol/fluticasone (Advair) MDI and diskus
– Budesonide/formoterol (Symbicort) turbuhaler
– add to therapy if patient has persistent dyspnea or recurrent exacerbations
– improve PFTs, QOL, decrease exacerbations
– Benefits much more modest than in asthma
COPD Management
Indications for long term oxygen therapy
• pO2 on room air of≤ 55 mmHg< 60 mm Hg if evidence of
– Polycythemia– Cor pulmonale– Right heart failure
• Mortality benefit
COPD Management
Surgery
• Lung Volume Reduction Surgery- benefits patients with upper lobe (heterogenous) emphysema and
poor exercise capacity
• Lung Transplantation- single or double lung- non-smoker (must have quit smoking)- generally age< 65 without significant cardiac, renal, hepatic disease- post-transplant survival is 5-6 years on average- death from infection (early) and chronic rejection (later)
COPD Management
End of Life Issues
• Empathetic, realistic conversations about illness• Opportunity to express wishes re: intubation
• Dyspnea- morphine po, sc, iv- benzodiazepines
• Cough- opioids (codeine, morphine)
• Secretions- scopolamine
What Decreases Mortality?
Non-Pharmacologic• Smoking cessation Yes• Flu shot No• Pneumonia vaccine No• Pulmonary Rehab ?
Pharmacologic• Oxygen Yes• Systemic Steroids No• Antibiotics No• SABA (Ventolin) No• Anti-cholinergics No• Theophylline No• Inhaled Steroids No• LABAs No• Combo ICS/LABA No
COPD
• Contrast from asthma
• Definition
• Pathophysiology
• Diagnosis
• Chronic Management
• Acute Management
Acute exacerbations of COPD
• Over 50% are associated with a bacterial infection• Decision to use antibiotics based on Anthonisen (Winnipeg)
criteria• Antibiotics are helpful if there are at least two of:
– Increased dyspnea– Increased volume of sputum– Increased purulence of sputum
Acute exacerbations of COPD
• Treatment:
– ABCs
– O2 sat monitoring and oxygen prn
– history and p/e to rule out other causes of dyspnea
– CXR, ABG, sputum C&S
– Bronchodilators
– systemic steroids: prednisone 50 mg/d x 10-14 days (?)
– antibiotics if purulent sputum
– NIPPV
Antibiotics for Community Acquired Pneumonia
Obstructive Sleep Apnea Syndrome
• Elevated Apnea-Hypopnea Index on Sleep study (Polysomnography)
AND
• Nighttime Symptoms: Snoring, witnessed apneas
OR
• Daytime Symptoms: Morning headache, daytime sleepiness
Obstructive Sleep Apnea Syndrome
• Apnea Hypopnea Index (AHI):– normal <5/hour– mild 5-15/hour– moderate 16-30/hour– severe >30/hour
• Treatment:– weight loss, avoid sedatives– positional therapy (off supine)– Non-invasive positive pressure therapy: CPAP / BiPAP– oral appliance, UPPP, tracheostomy less common / less effective
Pleural Effusion
Pleural Fluid Accumulation
• In normal pleural space, the rate of fluid formation is balanced by the rate of removal
• Rate of fluid formation is determined by the Starling equation
– hydrostatic forces push water out of vessel
– osmotic forces pull water back into vessel
• Pleural effusion is due to abnormalities in one of these processes
• Cell count and differential• Gram stain• Culture• AFB• Cytology
• LDH• Total protein• Glucose • pH
Pleural Effusion Evaluation
Light’s Criteria• pleural fluid protein/serum protein > 0.5• pleural fluid LDH / serum LDH > 0.6• pleural fluid LDH > 2/3 upper limit normal LDH
Any of these three criteria means fluid is EXUDATE
Pleural Effusion Evaluation
Many!
Transudate = fluid overload or reduced oncotic pressure (low albumin)heart, liver, kidney
Exudate = infectious inflammatory malignant iatrogenic
Pleural Effusion Etiology
• If exudate with no determined cause, you want to rule-out malignancyCT chest with contrast
pleuroscopy or VATSbronchoscopy
follow / repeat thoracentesis
Pleural Effusion Etiology
Treatment is palliative (reduce symptoms associated with effusion)Cure generally not possibleIn most cases, effusion will persist despite chemotherapy
Most places, patients admitted for symptomatic thoracentesis +/- tube drainage and pleurodesis (talc)
In Ottawa, patients mostly receiving PleurX (indwelling) catheters to allow home drainage
Malignant Pleural Effusions
Many causes - both benign and malignant
Solitary Pulmonary Nodule
Infectious granulomas fungal tuberculous
Benign neoplasm hamartoma lipoma
Vascular AVM
Developmental Bronchogenic Cyst
Inflammatory Wegener’s
Bronchogenic Cancer SCLC NSCLC - adenocarcinoma squamous large cell carcinoid
Metastatic Cancer breast colon others...
Many causes - both benign and malignant
Clinical (age, smoking history) and radiographic features help
Solitary Pulmonary Nodule
Benign Malignant
Size smaller (<1 cm) larger (>3 cm)
Margins round, smooth irregularspiculated
Over time stable growth
Calcification popcorn, centralconcentric, diffuse None or asymmetric
Management depends on risk of maligancy
Options:IgnoreFollow (repeat imaging within 3-6 months)BiopsyResect (almost never done without first attempting biopsy)
Solitary Pulmonary Nodule
Small Cell Lung Cancer
• Approximately 20% of lung cancers• more rapid doubling time, earlier metastases• responsive to chemotherapy and radiation but quickly relapses
• smokers• central airways• present with metastases• paraneoplastic syndromes
PEIR Digital Library http://peir2.path.uab.edu
• Limited (30-40%): involves only one hemithorax (maximum allowable for radiation portal)
- concurrent chemo + radiation- median survival 15-20 months
- (very small chance of cure)
• Extensive (60-70%): extends beyond hemithorax- Chemotherapy only- median 8-13 months
- (cure not possible)
Small Cell Lung Cancer
PEIR Digital Library http://peir2.path.uab.edu
Non Small Cell Lung Cancer
• 80% of all lung cancers• 10-15% survival at 5 years
• staging by TNM systemT = tumourN = nodeM = metastases
Up To Date www.utdol.com
Non Small Cell Lung Cancer
• Subtypes:- Adenocarcinoma (now most common)- Squamous cell carcinoma - Large cell carcinoma
PEIR Digital Library http://peir2.path.uab.edu
Bronchoalveolar Carinoma (BAC)
Non Small Cell Lung Cancer
• Treatment and prognosis depend on stage
• Early Stage (1 or 2)–Surgical resection if tolerated–Adjuvant chemotherapy to reduce risk of recurrence
• Later Stage (3B or 4)–Chemotherapy if performance status is reasonable–Palliative Radiotherapy for symptoms
• Majority of NSCLC will not be resectable and/or operable
u
The Plan...
• Spirometry
• Asthma
• COPD
• Sleep Apnea
• Pleural Effusion
• Lung Cancer
Good Luck
• Questions?
Top Related